Mitoxantrone in the treatment of relapsed and refractory acute leukemia

Mitoxantrone in the treatment of relapsed and refractory acute leukemia
Springer

Journal : Investigational New Drugs
Publisher: Springer Netherlands
ISSN: 0167-6997 (Print) 1573-0646 (Online)
Issue: Volume 3, Number 2 / June, 1985
DOI: 10.1007/BF00174171
Pages: 203-206
Subject Collection: Medicine
SpringerLink Date: Thursday, October 28, 2004

P. Meyer3, A. D. Ho2, G. Ehninger1, I. Mjaaland3, E. Heidemann1 and E. Seither2
(1) Medizinische Universitaetsklinik, Tuebingen, F.R.G.
(2) Medizinische Poliklinik der Universitaet, Heidelberg, F.R.G.
(3) Medizinische Poliklinik der Universitaet, Wuerzburg, F.R.G.
(4) Medizinische Poliklinik der Universitaet, D-8900 Wuerzburg, West Germany

Summary Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone. Mitoxantrone (Novantrone®; dihydroxyanthracenedione) was administered in a dose of 8–13 mg/m2 on five consecutive days. Five of 20 evaluable patients were induced into complete remission, one patient achieved a partial remission. Side-effects included moderate to severe bone marrow suppression, moderate mucositis and hair loss. No cardiotoxicity was observed. We believe that mitoxantrone is an active agent in the treatment of acute leukemia and suggest further studies in combination chemotherapy.

© Springer

This article may be viewed in its entirety by purchase at the website.